Meredith Morgan

Meredith Morgan, PhD

Associate Professor
Lawrence-Krause Professor of Radiation Oncology
Director of Radiation and Cancer Biology

1301 Catherine St.
Room 4326B Med Sci I
Ann Arbor, MI 48109-5637



Clinical Cancer Research cover article
Meredith Morgan's research featured on cover of Clinical Cancer Research

Dr. Morgan leads a laboratory focused on improving standard radiation and chemoradiation therapies through the use of novel agents targeting DNA damage response and repair. Her research program prioritizes pre-clinical research with strong clinical/translational relevance with an emphasis on pancreatic cancer. More specific areas of research interest include DNA double-strand break repair, DNA replication, cell cycle and biomarker development.

Areas of Interest

  • DNA damage and repair
  • DNA replication stress
  • Radiosensitization
  • Novel molecularly targeted therapeutics
  • Pancreatic cancer 

Honors & Awards

2016  First place poster award, A. Alfred Taubman Medical Institute 9th Annual Symposium
2012  “Highly Rated Paper” recognition, American Association for Cancer Research Annual Meeting
2011  “Highly Rated Paper” recognition, American Association for Cancer Research Annual Meeting
2004  Invited speaker at the American Association for Cancer Research Annual Meeting
2004  Cancer Biology Training Program, University of Michigan “The role of cell cycle checkpoints in gemcitabine-mediated radiosensitization.”
2001  Granted attendance to the American Association for Cancer Research, Pathobiology of Cancer Workshop. 


PhD, West Virginia University, 2002


  • R01 (CA163895), 09/01/2012-06/30/18, National Institutes of Health: Selective sensitization of pancreatic cancer to therapy by Chk1 and PARP1 inhibition, Role: Principal Investigator.
  • P50 (CA130810), 09/01/2010-08/31/17,  National Institutes of Health: Mechanism-Based use of Chk1 inhibitors in pancreas cancer, Role: Co-Investigator.
  • University of Michigan Fund for Discovery, 2/1/17-1/31/18: Therapeutic targeting of DNA repair for FBXW7 mutant colorectal cancers, Role: Principal Investigator.
  • U01 (CA216449), 04/01/2017-03/31/2022, National Institutes of Health: Sensitization to chemoradiation by therapeutic targeting of the DNA damage response, Role: Co-Investigator.                                  

Published Articles or Reviews

Selected from 48 publications

  • Zhang Q, Lawrence T, Morgan MA*, Sun Y*. FBXW7 facilitates non-homologous end-joining via K63-linked polyubiquitylation of XRCC4. Molecular Cell, 61:419-33, 2016.(*Equal contribution)
  • Parsels L, Tanska D, Parsels J, Zabludoff S, Cuneo K, Lawrence T, Maybaum J*, Morgan M*. Dissociation of gemcitabine chemosensitization by CHK1 inhibition from G2 checkpoint abrogation. Cell Cycle, 15:730-9, 2016.
  • Kausar T, Schreiber J, Karnak D, Parsels LA, Parsels JD, Davis MA, Zhao L, Maybaum J, Lawrence TS, and Morgan MA. Sensitization of pancreatic cancers to gemcitabine-chemoradiation by WEE1 kinase inhibition depends on homologous recombination repair. Neoplasia, 17:757-66, 2015.
  • Zhang Q, Zhang Y, Parsels JD, Lohse I, Lawrence TS, Pasca di Magliano M, Sun Y, Morgan MA. Fbxw7 deletion accelerates KrasG12D –driven tumorigenesis via Yap accumulation. Neoplasia 11:666-73, 2016.
  • Morgan MA,  Lawrence TS. Molecular Pathways: Overcoming radiation resistance by targeting the DNA response pathways. Clin Cancer Res, 21:2898-2904, 2015.
  • Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Roberson JR, Marsh KB, Davis MA, Maybaum J, Lawrence TS, and Morgan MA. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer. Clin Cancer Res, 20:5085-96, 2014.
  • Morgan MA, Parsels LA, Maybaum J, and Lawrence TS: Improving the efficacy of chemoradiation with targeted agents. Cancer Discovery, 4:1-12, 2014.


Web Sites